In this episode of our Road To A Cure series, we talk with oncologist and researcher Dr. Erika Hamilton about the practice-changing developments of the past 15 months. This is a timely discussion as research continues to catch up to need in our lives with metastatic breast cancer. 2022 brought the big news that an anti-body drug conjugate, Enhertu, was delivering results in people with what was then known as HER2-negative breast cancer. Suddenly the term HER2-Low was everywhere. Of course, the news in 2022 didn’t stop with Enhertu and here we talk about how the big developments of last year are continuing into 2023. We find out what is coming in each subtype, where there are challenges, and what research is making news right now.Dr. Hamilton is the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, as well as a partner with Tennessee Oncology PLCC. She currently serves on ASCO’s Cancer Research Committee as well as the 2023-2025 Scientific Committee Co-Chair of the ESMO Breast Cancer Meeting.